Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedApr 15, 2026
DataAggregated Company Financials
Companies61
  • 7D5.8%
  • 3M-16.9%
  • 1Y13.5%
  • YTD-12.9%

The Life Sciences industry is up 5.8% in the last week, with Thermo Fisher Scientific up 7.7%. During this same period, the Atlantic International underperformed, falling 25%. This means that the industry has gained 13% over the past year. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Apr 2026US$580.2bUS$147.8bUS$14.1b39x41.2x3.9x
Fri, 13 Mar 2026US$562.3bUS$147.8bUS$14.0b32.9x40.1x3.8x
Sun, 08 Feb 2026US$618.0bUS$147.4bUS$12.9b36.4x48.1x4.2x
Tue, 06 Jan 2026US$689.0bUS$145.8bUS$12.4b36.8x55.7x4.7x
Thu, 04 Dec 2025US$668.5bUS$145.8bUS$12.5b36.5x53.6x4.6x
Sat, 01 Nov 2025US$639.2bUS$145.4bUS$12.2b36x52.6x4.4x
Mon, 29 Sep 2025US$552.3bUS$144.3bUS$14.6b29.4x37.9x3.8x
Wed, 27 Aug 2025US$583.2bUS$144.1bUS$14.5b28.8x40.2x4x
Fri, 25 Jul 2025US$565.9bUS$143.6bUS$8.8b41.6x64.4x3.9x
Sun, 22 Jun 2025US$516.2bUS$142.9bUS$9.2b35.3x56.3x3.6x
Tue, 20 May 2025US$519.6bUS$142.7bUS$9.1b33.4x57.2x3.6x
Thu, 17 Apr 2025US$517.3bUS$142.6bUS$10.0b35x52x3.6x
Sat, 15 Mar 2025US$581.3bUS$143.1bUS$9.8b38.6x59.5x4.1x
Mon, 10 Feb 2025US$658.3bUS$143.1bUS$11.1b38.1x59.3x4.6x
Wed, 08 Jan 2025US$673.1bUS$142.4bUS$10.2b43.9x66x4.7x
Fri, 06 Dec 2024US$671.2bUS$142.4bUS$10.2b43.6x65.7x4.7x
Sun, 03 Nov 2024US$689.4bUS$142.2bUS$8.9b39.1x77.3x4.8x
Tue, 01 Oct 2024US$748.6bUS$141.8bUS$8.5b39x88.1x5.3x
Thu, 29 Aug 2024US$745.7bUS$141.8bUS$8.5b37.7x87.8x5.3x
Sat, 27 Jul 2024US$716.0bUS$141.0bUS$12.5b37.3x57.4x5.1x
Mon, 24 Jun 2024US$694.3bUS$141.3bUS$12.2b38.6x57x4.9x
Wed, 22 May 2024US$739.8bUS$141.5bUS$12.4b38.5x59.5x5.2x
Fri, 19 Apr 2024US$682.0bUS$142.0bUS$12.8b41x53.3x4.8x
Sun, 17 Mar 2024US$742.0bUS$142.1bUS$12.8b43.9x57.8x5.2x
Tue, 13 Feb 2024US$709.9bUS$141.9bUS$12.7b39.2x55.8x5x
Thu, 11 Jan 2024US$692.8bUS$153.9bUS$14.2b36.6x48.9x4.5x
Sat, 09 Dec 2023US$648.8bUS$153.7bUS$14.0b35.2x46.3x4.2x
Mon, 06 Nov 2023US$595.2bUS$153.9bUS$11.0b31.5x54x3.9x
Wed, 04 Oct 2023US$640.4bUS$154.6bUS$11.2b32.3x57.2x4.1x
Fri, 01 Sep 2023US$733.5bUS$154.6bUS$11.2b32.9x65.4x4.7x
Sun, 30 Jul 2023US$734.3bUS$154.7bUS$11.6b31.5x63.2x4.7x
Tue, 27 Jun 2023US$687.9bUS$152.4bUS$12.5b29.3x55x4.5x
Thu, 25 May 2023US$671.4bUS$152.2bUS$12.5b27.8x53.7x4.4x
Sat, 22 Apr 2023US$728.5bUS$154.6bUS$10.8b29.9x67.4x4.7x
Price to Earnings Ratio

67.4x


Total Market Cap: US$728.5bTotal Earnings: US$10.8bTotal Revenue: US$154.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 57.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 41.2x which is lower than its 3-year average PE of 57.4x.
  • The 3-year average PS ratio of 4.5x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 9.3% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market4.44%
Healthcare2.18%
Life Sciences5.83%
Clinical Research and Equipment5.83%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$527.227.7%
+US$14.0b		19.6%PE29.2x
DHR DanaherUS$198.614.0%
+US$5.4b		4.6%PE39x
WAT WatersUS$330.987.7%
+US$2.3b		2.3%PE50.6x
A Agilent TechnologiesUS$120.395.7%
+US$1.8b		16.7%PE26.4x
MTD Mettler-Toledo InternationalUS$1.34k5.6%
+US$1.4b		28.2%PE31.3x

Latest News

WAT
US$330.98
Waters
7D
7.7%
1Y
2.3%
TMO
US$527.22
Thermo Fisher Scientific
7D
7.7%
1Y
19.6%
LAB
US$0.89
Standard BioTools
7D
-4.3%
1Y
-23.0%

LAB: Completed Buybacks And 2026 Outlook Will Support Future Upside

Analysts have nudged their price target on Standard BioTools slightly higher to $1.35, reflecting minor tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions, while keeping their overall valuation framework broadly unchanged. What's in the News Completion of a share repurchase program, with 13,603,617 shares bought back for a total of $35.91 million under the buyback announced on March 1, 2024 (Key Developments).
HBIO
US$4.91
Harvard Bioscience
7D
-9.1%
1Y
24.3%

HBIO: Reverse Split And Cost Savings Plan Will Support Future Upside Potential

Narrative Update Analysts have reset their price target on Harvard Bioscience to $6, largely reflecting the recent 1:10 reverse split and the updated revenue expectations in their models. Analyst Commentary Recent research updates on Harvard Bioscience focus on the technical impact of the 1:10 reverse split and revised revenue assumptions, rather than any major shift in the underlying story.
QTRX
US$3.39
Quanterix
7D
-4.2%
1Y
-36.8%

Quanterix: No Green Shoots

Apr 10
MTD
US$1,341.53
Mettler-Toledo International
7D
5.6%
1Y
28.2%

MTD: Extensive Buybacks And 2026 Sales Outlook Will Support Future Upside

Analysts have trimmed their price target for Mettler-Toledo International by about $7 to $1,498, reflecting small adjustments to fair value, discount rate, revenue growth and profit margin assumptions, along with a slightly lower future P/E estimate. What's in the News Mettler-Toledo International reported completion of a long running share repurchase program first announced on February 9, 2010, having bought back a total of 17,805,987 shares, or 66.06%, for US$9,514.61m under the authorization.
NAUT
US$3.06
Nautilus Biotechnology
7D
-1.9%
1Y
297.4%
A
US$120.39
Agilent Technologies
7D
5.7%
1Y
16.7%

A: New Diagnostic Expansion And Guidance Will Support Long Term Upside

Analysts have slightly reduced their price target on Agilent Technologies by about $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. They indicate that the overall outlook remains largely intact.
RGEN
US$131.03
Repligen
7D
13.7%
1Y
3.5%

RGEN: Multi Year Guidance And M&A Dry Powder Will Support Future Upside

Narrative Update on Repligen The analyst price target for Repligen has been adjusted slightly lower, with the updated fair value moving from about $186.82 to $183.88 as analysts factor in recent target cuts, alongside generally positive views on guidance and execution. Analyst Commentary Recent Street research on Repligen clusters around a group of target cuts following the latest Q4 report and FY26 outlook, alongside a smaller number of target increases.
OABI
US$1.46
OmniAb
7D
-3.3%
1Y
-22.8%

OABI: Updated Bylaws And 2026 Revenue Guidance Will Support Long Term Upside

Analysts kept their price target on OmniAb broadly aligned with prior views, citing relatively steady assumptions around fair value, growth and profitability that offset only minor tweaks to the discount rate and future P/E multiple. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million, giving you a reference point for the company’s own outlook on its top line for that year (Key Developments).
DHR
US$198.61
Danaher
7D
4.0%
1Y
4.6%

Danaher: A Great Way To Play Healthcare For Long-Term Dividend Growth Investors

Apr 06
TECH
US$58.66
Bio-Techne
7D
9.0%
1Y
14.9%

TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings Multiple

Analysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).
ATLN
US$2.26
Atlantic International
7D
-24.9%
1Y
-38.3%
NOTV
US$0.24
Inotiv
7D
-3.0%
1Y
-86.2%

NOTV: Future Upside Will Depend On Meeting Nasdaq Bid Price Requirement

Analysts have lowered their price target on Inotiv by $1.50 to reflect updated fair value estimates, a slightly adjusted discount rate, and modest changes to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Bearish analysts lowering the price target by $1.50 are signaling a more cautious stance on how Inotiv is priced relative to updated fair value estimates.
IQV
US$175.28
IQVIA Holdings
7D
2.7%
1Y
17.5%

IQV: Future Returns Will Lean On AI Driven Clinical Trial Upswing

Narrative Update on IQVIA Holdings The analyst price target framework for IQVIA Holdings is unchanged at $200. Recent research points to modest adjustments in revenue growth, profit margin and future P/E assumptions, as analysts highlight the company's data analytics capabilities, AI related cost efficiencies in clinical trials and expectations for increased trial activity into 2026.
CSBR
US$5.73
Champions Oncology
7D
-6.7%
1Y
-28.7%